• Br J Gen Pract · Aug 2024

    Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.

    • May Ee Png, Victoria Harris, Jenna Grabey, Nigel D Hart, Bhautesh D Jani, Daniel Butler, Andrew Carson-Stevens, Maria Coates, Lucy Cureton, Melissa Dobson, Jienchi Dorward, Philip Evans, Nick Francis, Oghenekome A Gbinigie, Gail Hayward, Jane Holmes, Kerenza Hood, Saye Khoo, Haroon Ahmed, Mark Lown, Micheal McKenna, Sam Mort, Jonathan S Nguyen-Van-Tam, Najib M Rahman, Duncan B Richards, Nicholas Pb Thomas, Oliver van Hecke, Richard Hobbs, Paul Little, Ly-Mee Yu, Christopher C Butler, Stavros Petrou, and PANORAMIC Trial Collaborators.
    • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
    • Br J Gen Pract. 2024 Aug 1; 74 (745): e570e579e570-e579.

    BackgroundThe cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations.AimTo evaluate the cost-effectiveness of molnupiravir relative to usual care alone among mainly vaccinated community-based people at higher risk of severe outcomes from COVID-19 over 6 months.Design And SettingAn economic evaluation of the PANORAMIC trial in the UK.MethodA cost-utility analysis that adopted a UK NHS and personal social services perspective and a 6-month time horizon was performed using PANORAMIC trial data. Cost-effectiveness was expressed in terms of incremental cost per quality-adjusted life year (QALY) gained. Sensitivity and subgroup analyses assessed the impacts of uncertainty and heterogeneity. Threshold analysis explored the price for molnupiravir consistent with likely reimbursement.ResultsIn the base-case analysis, molnupiravir had higher mean costs of £449 (95% confidence interval [CI] = 445 to 453) and higher mean QALYs of 0.0055 (95% CI = 0.0044 to 0.0067) than usual care (mean incremental cost per QALY of £81 190). Sensitivity and subgroup analyses showed similar results, except for those aged ≥75 years, with a 55% probability of being cost-effective at a £30 000 per QALY threshold. Molnupiravir would have to be priced around £147 per course to be cost-effective at a £15 000 per QALY threshold.ConclusionAt the current cost of £513 per course, molnupiravir is unlikely to be cost-effective relative to usual care over a 6-month time horizon among mainly vaccinated patients with COVID-19 at increased risk of adverse outcomes, except those aged ≥75 years.© The Authors.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…